| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
81.50(B) |
| Last
Volume: |
7,436,599 |
Avg
Vol: |
8,754,576 |
| 52
Week Range: |
$65.27 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,348 |
387,051 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-09-10 |
4 |
D |
$76.00 |
$11,324 |
D/D |
(149) |
30,124 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
519 |
30,273 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-09-10 |
4 |
D |
$76.00 |
$91,428 |
D/D |
(1,203) |
109,003 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,619 |
110,206 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-09-10 |
4 |
D |
$76.00 |
$97,128 |
D/D |
(1,278) |
71,631 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,779 |
72,909 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-08-10 |
4 |
D |
$80.00 |
$104,480 |
D/D |
(1,306) |
29,754 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,484 |
31,060 |
|
- |
|
| Telman Deborah H |
EVP, Corporate Affairs & GC |
• • – |
2023-07-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,289 |
6,491 |
|
- |
|
| Telman Deborah H |
EVP, Corporate Affairs & GC |
• • – |
2023-07-25 |
4 |
D |
$77.23 |
$322,358 |
D/D |
(4,174) |
4,433 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2023-07-24 |
4 |
D |
$77.66 |
$246,493 |
D/D |
(3,174) |
48,326 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2023-07-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,505 |
51,500 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-07-20 |
4 |
AS |
$80.00 |
$400,000 |
D/D |
(5,000) |
107,587 |
|
-6% |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-06-13 |
4 |
AS |
$76.90 |
$114,197 |
D/D |
(1,485) |
29,402 |
|
-1% |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-06-10 |
4 |
D |
$78.12 |
$101,087 |
D/D |
(1,294) |
30,887 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,779 |
32,181 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2023-06-10 |
4 |
D |
$78.12 |
$99,369 |
D/D |
(1,272) |
43,995 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,730 |
45,267 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-06-10 |
4 |
D |
$78.12 |
$95,228 |
D/D |
(1,219) |
73,701 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,618 |
74,920 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-06-10 |
4 |
D |
$78.12 |
$11,952 |
D/D |
(153) |
26,576 |
|
- |
|
| Patterson Sandra |
SVP, Controllership |
• • – |
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
517 |
26,729 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-06-10 |
4 |
D |
$78.12 |
$266,311 |
D/D |
(3,409) |
266,125 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2023-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,346 |
269,534 |
|
- |
|
2493 Records found
|
|
Page 3 of 100 |
|
|
0.74 (1.12%) 
